The Atomo (ASX:AT1) share price has shot up 9%. Here's why

The diagnostics company released its fourth-quarter business update today.

| More on:
a man sits on a rocket propelled office chair and flies high above a city

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Atomo Diagnostics Ltd (ASX: AT1) share price has rocketed in opening trade today after the medical device company released its fourth-quarter results to the ASX.

At the time of writing, the Atomo share price is trading 9.30% higher at 23.5 cents apiece.

How did Atomo perform for the quarter?

The Atomo share price is soaring after the company reported a robust performance during the fourth quarter.

For the period ending 30 June, Atomo recorded cash receipts from customers of $717,000, bringing the full-year to $8.01 million. It's worth noting that shortly after the close of Q4 FY21, a further $750,000 was received.

Sales represented a total of $6.7 million for the 2021 financial year, up by 25% when compared to FY20 ($5.4 million).

Atomo ended the quarter with a cash balance of $17.95 million.

Pleasingly, the company is expecting sales to expand rapidly in FY22, with key multi-year agreements secured with Viatris and Unitaid. HIV self-testing kits – designed and manufactured by Atomo – will be sent to 135 low and middle-income countries.

During late in the fourth quarter, the company received an initial order of 250,000 units under the Unitaid purchasing program. These products have since been shipped and delivered, with the majority of the order to be fulfilled in Q1 FY22.

To support the large order and potential future orders, Atomo has expanded operations at its South African facility. This includes additional assembly and packaging lines, as well as hiring and training further staff.

Across in the United States market, Atomo revealed that discussions with Access Bio were ongoing in relation to delivering its COVID-19 antibody test kits. Previously, Access Bio ordered 260,000 devices from Atomo, in part of the take-or-pay commitment of 2 million units by 30 September.

In Australia, interest has soared regarding Atomo's COVID-19 rapid tests. The company has engaged with the Australian Aged Care market to develop its first aged care COVID-19 rapid antigen screening program.

Atomo share price summary

Despite the positive turn of events, Atomo shares have gradually trekked lower in the past 12 months, posting a 44% loss. In 2021 alone, the company's share price is down around 30%.

Atomo has a market capitalisation of roughly $87.8 million, with more than 408 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »